Skip to main navigation Skip to search Skip to main content

CAR T-Cell Therapy for Cancer: Updates and Challenges for Response Assessment

  • Dorine de Jong
  • , Jeremy P. McGale
  • , Timothy J. Robinson
  • , Matthew J. Liao
  • , Jeeban P. Das
  • , Ajay Major
  • , Kathleen M. Capaccione
  • , Colton Ladbury
  • , Jorge Mansilla-Soto
  • , Hong Ma
  • , Karine A. Al Feghali
  • , Andre H. Goy
  • , Egesta Lopci
  • , Ran Reshef
  • , Lawrence H. Schwartz
  • , Roch Houot
  • , Laurent Dercle
  • RefleXion Medical, Inc.
  • Columbia University
  • Yale University
  • Memorial Sloan-Kettering Cancer Center
  • University of Colorado Anschutz Medical Campus
  • City of Hope National Med Center
  • Moffitt Cancer Center
  • IRCCS Istituto Clinico Humanitas - Rozzano (Milano)
  • CHU de Rennes

Research output: Contribution to journal › Article › peer-review

Abstract

Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment landscape for multiple hematologic malignancies, demonstrating a clear curative potential in select cases. Since 2017, 7 CAR T-cell products have indications approved by the Food and Drug Administration, and research is continuously evolving with the intent of enhancing CAR T-cell efficacy while reducing side effects and the risk of relapse. Nuclear medicine has played a crucial role throughout this optimization process, assisting initial staging, treatment response assessment, and adverse-effect monitoring. This review provides an introduction to CAR T-cell therapy and highlights goldstandard nuclear medicine practices and imaging innovations for use in the care of oncology patients. Additionally, it emphasizes the need for continuing innovation in medical imaging as the field progresses.

Original languageEnglish
Pages (from-to)1021-1031
Number of pages11
JournalJournal of nuclear medicine : official publication, Society of Nuclear Medicine
Volume67
Issue number7
DOIs
StatePublished - Jul 2026

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • CAR T-cell
  • hematologic malignancies
  • immunotherapy-related toxicity
  • nuclear medicine
  • therapy response assessment

Fingerprint

Dive into the research topics of 'CAR T-Cell Therapy for Cancer: Updates and Challenges for Response Assessment'. Together they form a unique fingerprint.

Cite this